| [Abstract] Liuweiwuling Tablets (LWWL), as the first-line drug for the treatment of chronic hepatitis B (CHB) with elevated aminotransferase, has a significant effect on liver protection and enzyme reduction. In recent years, with the expansion of its clinical treatment spectrum, it has been found that LWWL has good efficacy in liver disease such as drug-induced liver injury (DILI), non-alcoholic fatty liver disease (NAFLD), and alcoholic liver disease (ALD), viral liver disease, and liver disease pathologic processes such as liver fibrosis. A number of basic studies have also evaluated the pharmacological effects of LWWL in liver diseases, and the mechanism of action mainly involves the regulation of several immune-related pathways. We will review the pharmacological roles and mechanisms of LWWL in different liver diseases, the progress of clinical application, and the pharmacodynamic agents, so as to provide solid evidence for the greater role of LWWL in liver diseases. |